From upfront discounts to rebate-based pricing—QuicksortRx gives you the tools to stay compliant, plan, and act quickly in a shifting regulatory environment.
Request your personalized analysis.
On July 30 HRSA announced a proposed 340B Rebate Model Pilot Program. While this pilot is on hold now, it could shift the benefit from upfront discounts to rebate-based reimbursements for over 400 NDCs tied to 10 IRA-selected drugs for 2026 and 15 selected drugs for 2027.
For covered entities, this would mean paying full WAC upfront—then waiting for rebate checks later. That delay could put significant cash flow pressures on health systems.
We built a tool to help our customers navigate the change.
Equip yourself to confidently advise finance leaders with insights at your fingertips.
Your pricing data showing WAC spend for over 400 IRA-linked NDCs
Assess impact for 2026 and additional 2027 projections
Estimated rebate lag effects on cash flow
Detailed net exposure breakdown by drug and category
The 340B Rebate Pilot Report is just the start. We don’t wait for policy to finalize—we build so you can act now. We’ll monitor policy changes and explore ways to with real-time rebate reconciliation, increased price transparency, and future tools for inpatient and infusion workflows.